West Pharmaceutical Services (NYSE:WST) Stock Price Target Raised at TD Cowen

West Pharmaceutical Services (NYSE:WST) had its price target lifted by TD Cowen from $420.00 to $500.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

WST has been the topic of several other research reports. Morgan Stanley upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $365.00 to $400.00 in a report on Tuesday, September 22nd. UBS Group raised their target price on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Evercore reiterated an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. Citigroup lifted their target price on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $409.67.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $412.73 on Friday. The stock’s fifty day simple moving average is $367.76 and its 200 day simple moving average is $313.21. The stock has a market capitalization of $29.05 billion, a price-to-earnings ratio of 46.32, a PEG ratio of 2.75 and a beta of 1.13. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $438.27.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The business had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. During the same period in the prior year, the business posted $1.96 earnings per share. West Pharmaceutical Services’s revenue was up 8.7% compared to the same quarter last year. As a group, sell-side analysts forecast that West Pharmaceutical Services will post 9.45 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be issued a $0.26 dividend. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio is currently 11.67%.

Insider Buying and Selling

In related news, VP Annette Favorite sold 8,135 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the transaction, the vice president owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 15,659 shares of company stock valued at $5,443,749 in the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Evergreen Capital Management LLC increased its stake in West Pharmaceutical Services by 2.5% in the third quarter. Evergreen Capital Management LLC now owns 1,131 shares of the medical instruments supplier’s stock valued at $419,000 after acquiring an additional 28 shares during the last quarter. Greenleaf Trust raised its position in West Pharmaceutical Services by 4.1% during the second quarter. Greenleaf Trust now owns 843 shares of the medical instruments supplier’s stock valued at $303,000 after purchasing an additional 33 shares in the last quarter. Wealth Alliance LLC raised its position in West Pharmaceutical Services by 3.8% during the first quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock valued at $237,000 after purchasing an additional 35 shares in the last quarter. 55 North Private Wealth LLC lifted its stake in West Pharmaceutical Services by 5.4% during the third quarter. 55 North Private Wealth LLC now owns 708 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 36 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its stake in West Pharmaceutical Services by 4.1% during the third quarter. D.A. Davidson & CO. now owns 909 shares of the medical instruments supplier’s stock worth $337,000 after purchasing an additional 36 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Key West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.